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http://dx.doi.org/10.1016/j.ccr.2013.07.007SUMMARYA causal role of gene amplification in tumorigenesis is well known, whereas amplification of DNA regulatory
elements as an oncogenic driver remains unclear. In this study, we integrated next-generation sequencing
approaches to map distant estrogen response elements (DEREs) that remotely control the transcription of
target genes through chromatin proximity. Two densely mapped DERE regions located on chromosomes
17q23 and 20q13 were frequently amplified in estrogen receptor-a-positive luminal breast cancer. These
aberrantly amplified DEREs deregulated target gene expression potentially linked to cancer development
and tamoxifen resistance. Progressive accumulation of DERE copies was observed in normal breast progen-
itor cells chronically exposed to estrogenic chemicals. These findings may extend to other DNA regulatory
elements, the amplification of which can profoundly alter target transcriptome during tumorigenesis.INTRODUCTION
For more than two decades, considerable efforts aimed at iden-
tifying oncogenes located near or within amplified genomic re-
gions in cancer have been at the forefront of cancer research
(Albertson 2006; Lupski and Stankiewicz, 2005; Stephens et al.,
2011). A long-standing view is that these amplification events
contribute to increased expression dosages of genes located in
the regions for oncogenesis. The first oncogene,MYCN,mappedSignificance
Genomic amplification of 17q23 and 20q13 is a known progn
oncogenic drivers within these genomic regions, only a handfu
integrative analyses, we discover that densely estrogen recept
to breast tumorigenesis. Increased DERE copies enhance chro
of genes associated with tumor-suppressor and apoptosis pa
may be a relevant factor in the development of a previously unto chromosome 2p24, is amplified up to 300 copies in homoge-
neously staining regions of neuroblastomas (Schwab et al.,
1983). High MYCN transcription levels typically accompanied
with this genomic copy-number gain (Schwab, 1999). ERBB2,
localized on chromosome 17q21, is another well-characterized
gene frequently amplified and overexpressed in breast cancer
(Santarius et al., 2010; Slamon et al., 1987). These findings indi-
cate that genomic amplification is amajormechanism underlying
the activation of oncogenes during tumor development.ostic factor in breast cancer. Despite exhaustive search for
l of putative oncogenes have been identified. By conducting
or-a-bound DEREs localized in these regions may contribute
matin interactions, leading to the transcriptional repression
thways. The increased frequency of chromatin interactions
described subtype of tamoxifen-resistant breast cancer.
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Estrogen-Driven DERE Amplification in Breast CancerIntensive efforts have recently been undertaken to globally
screen for and analyze genomic amplicons in breast cancer
(Curtis et al., 2012; Nikolsky et al., 2008; Pollack et al., 2002; San-
tarius et al., 2010). In a study of 2,000 primary breast tumors,
copy-number gains were frequently found on chromosomes
1q, 7p, 8, 11q, 14q, 16, 17q, and 20q (Curtis et al., 2012). Onco-
genes including PIK3CA, EGFR, ERBB2, and FOXA1 located in
these amplicons were overexpressed in specific breast cancer
subtypes. However, other copy-number gains were not neces-
sarily correlated with upregulation of candidate loci found in am-
plicons (Cancer GenomeAtlas Network, 2012; Curtis et al., 2012;
Santarius et al., 2010). In other global surveys, >80%of amplified
or structurally rearranged regions did not harbor protein-coding
ormicroRNA loci aberrantly expressed in cancer (Hampton et al.,
2009; Stephens et al., 2011). In those cases, copy-number gains
of DNA regulatory elements with the strong potential to affect
target gene transcription have often been overlooked. Transcrip-
tion repressors or activators usually bind to these regulatory
regions located near transcription start sites (TSSs) of genes.
Furthermore, increasing evidence has recently indicated that
DNA regulatory regions are remotely located downstream or
far upstream from TSSs or even on different chromosomes.
Through intra- or inter-chromatin looping, these regulatory ele-
ments are brought near TSSs for transcriptional repression or
activation of target genes (Carroll et al., 2006; Fullwood et al.,
2009; Hsu et al., 2010; Hu et al., 2008; Visel et al., 2009). Frequent
chromatin interactions may increase DNA breaks at or nearby
the looping sites, contributing to genomic instability in cancer
cells. Inappropriate DNA repair may lead to genomic fusion
and duplication of regulatory elements and gene promoters
(Berger et al., 2011; Lin et al., 2009; Mani et al., 2009). In addition
to oncogene amplification, we hypothesize that genomic ampli-
fication of DNA regulatory elements offers another mechanistic
explanation for extensive transcription alterations during
tumorigenesis.
Our goal in this study was to comprehensively map distant
estrogen response elements (DEREs) in breast cancer that regu-
late the transcription of remote target genes using integrated
next-generation sequencing approaches. We also examined
the role of estrogen receptor activation through its ligand estra-
diol in enhancing DERE-mediated transcriptional control and
aberrant gains of DERE copy. Furthermore, we addressed
whether DERE amplification can be associated with endocrine
resistance in breast cancer.
RESULTS
Integrative Analyses Identify Densely Mapped DERE
Regions
To globally survey estrogen-induced chromatin interaction
events, we performed chromosome conformation capture (3C)
coupled with paired-end sequencing in MCF-7 cells stimulated
with E2 (17b-estradiol, 70 nM) for 24 hr (Dekker et al., 2002;
Hage`ge et al., 2007). Based on our previous study, progressive
increases in chromatin interaction frequency occurred during
this stimulation period (Hsu et al., 2010). Crosslinked chromatin
was digested with BamHI for subsequent diluted ligation (Fig-
ure 1A, STEP 1). Ligated DNA fragments attributed to different
chromosome regions coming into proximity through chromatin198 Cancer Cell 24, 197–212, August 12, 2013 ª2013 Elsevier Inc.looping were subjected to paired-end sequencing (total 0.3
billion 51-base pair [bp] sequence reads; Table S1 available
online). Poisson regression modeling was used to determine
true chromatin-looping events (FDR = 8.35%). To demonstrate
the reliability of this 3C assay, reproducibility, saturation, and
sensitivity analyses were also conducted on two biologic repli-
cates (Figures S1A and S1B; Table S2).
Because this sequencing approach may capture structural
fusions, we comprehensively mapped all putative translocation
sites in MCF-7 cells by mate-pair sequencing with an 313
converge of the genome (total 2.4 billion 51-bp sequence reads;
TableS3). All potential false-positive fusionsproducedby random
ligations were eliminated using Poisson regression modeling
(FDR < 0.000001). A total of 429 translocation fusions were iden-
tified in the MCF-7 genome (Table S4). By excluding these trans-
location events from the 3C data set, 6,634 and 8,269 chromatin
interaction events were unique to the control and E2-stimulated
cells, respectively (Figure 1A, STEP 2; Tables S5 and S6).
To further define DERE-associated chromatin interactions, we
performed a time-course chromatin immunoprecipitation using
an estrogen receptor-a (ERa) antibody coupled with single-end
sequencing (ERa ChIP-seq) in MCF-7 cells stimulated with E2
for 0, 0.5, 1, and 24 hr (Figure 1A, STEP3). A total of 0.3 billion
51-bp sequence reads were processed, and 58.9% of those
reads mapped to unique chromosome locations (Table S7).
The wBELT Peak Calling program was applied to identify specif-
ically ERa-bound DEREs upon E2 stimulation (Hsu et al., 2010).
De novo binding events (n = 11,397) accumulated by 1 hr and
decreased by 24 hr. Integration with the aforementioned chro-
matin looping data, we found 505 DERE-associated chromatin
interaction events after E2 treatment for a 24 hr period (Figure 1A,
STEP3). Notably, 408 pre-existing interactions simultaneously
disappeared, consistently supporting our previous finding that
ERa binding also results in chromatin dissociation in target sites
(Hsu et al., 2010). In addition, 76 of these pre-existing interaction
events remained unchanged upon E2 stimulation. When catego-
rizing these interaction sites based on their genomic locations,
we found that DEREs from either the same or different chromo-
somes frequently interacted with each other, accounting for
49% of all interaction events (Figure 1B). As expected, DEREs
were found to interact with an overall large number of target
genes through intra- and interchromatin looping (n = 467). How-
ever, only 4%–8% of all DERE interactions occurred near pro-
moter regions while the majority (37%–39%) of these interaction
sites occurred within gene bodies (Figure 1B).
Interestingly, DERE interaction sites were frequently clustered
in specific chromosome regions, such as 1p13, 3p14, 17q23,
and 20q13 (Figures 1C and S1C). Pairwise heat maps depicting
interaction frequencies between different DEREs showed that
chromatin segments on 20q13 or 17q23 most frequently inter-
acted with other segments on different chromosomes (see pur-
ple arrows in Figure 2A). In addition, these two regions displayed
the highest density (46–51 sites per megabase) of DEREs bound
by ERa compared to other genomic regions (e.g., 3q23, two to
five sites per megabase) after E2 treatment (Figure 2B, blue
and red landscape maps; Table S8). We also found that these
two regions contained hot spots for genomic translocations (Fig-
ure 2B, purple maps; Figures S2A and S2B). When surveying the
entire MCF-7 genome, we observed that 23.6% of all fusion
Figure 1. Integrative Mapping of ERa-Mediated Chromatin Interactions Based on Next-Generation Sequencing Approaches
(A) Integrative scheme of identifying ERa/DERE-mediated chromatin interaction sites in E2-stimulated MCF-7 human breast cancer cells. 3C assay coupled with
paired-end sequencingwas performed on both untreated (Ctrl) and estrogen-treated (E2, 70 nM)MCF-7 cells to survey chromatin interaction events in a genome-
wide manner (STEP 1; see also Figures S1A and S1B and Tables S1 and S2). To identify genuine interaction sites, genomic fusions and self-ligated fragments
mapped by mate-pair sequencing were filtered-out from the 3C-seq data set (STEP 2; see also Tables S3, S4, S5, and S6). The filtered data were then integrated
with ERa ChIP-seq data sets (0 and 24 hr, respectively) and distant estrogen response elements (DEREs) were mapped to define DERE-associated chromatin
interaction events (STEP 3; see also Table S7).
(B) Genomic distribution of ERa-mediated chromatin interaction sites. ERa-mediated interaction sites mapped within 10 kb regions of DEREs, which have no
known target genes, were defined as DERE-DERE interactions. In the target loci category, the regions within 10 kb upstream and 1 kb downstream of the TSS of a
gene were defined as promoters. ‘‘Others’’ were defined as ERa-mediated interaction sites mapped in gene-desert regions.
(C) Circular visualization of ERa-mediated interactions upon E2 stimulation. Circular plots depict interactive loci of different chromatin loops using the Circos
software (http://mkweb.bcgsc.ca/circos/). Chromosomes are individually colored. The locations of DEREs are represented as lines outside the chromosomes
‘‘circle.’’ Four clustered DEREs were identified in 1p13, 3p14, 17q23, and 20q13 regions (see also Figure S1C).
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Estrogen-Driven DERE Amplification in Breast Cancerevents occurred between 17q23 and 20q13 (Figure 2C). More-
over, these densely localized DEREs were frequently mapped
near or at clustered breakpoints in 17q23 and 20q13 regions(five to ten breakpoints per megabase) compared to other non-
clustered regions (p < 0.001; Figure 2D). Additional data indicate
that estrogenic stimulation leads to distant chromatinCancer Cell 24, 197–212, August 12, 2013 ª2013 Elsevier Inc. 199
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Figure 2. Colocalization of Densely ERa-Bound DEREs and Translocation-Susceptible Regions
(A) Heat maps of DERE-DERE chromatin interactions. Frequencies of DERE-DERE interactions in p and q arms of individual chromosomes were plotted. Purple
arrows indicate two major sites of DERE-DERE interactions on 20q13 and 17q23, respectively. See also Figures S2C–S2E for a proposed model of DERE-DERE
fusions and amplification.
(B) Genomic maps of translocation breakpoints and ERa-bound DEREs in three representative regions (3q23, 17q23, and 20q13) of MCF-7 cells. MCF-7 cells
stimulated with E2 (70 nM) in a time-dependent manner (0, 0.5, 1, and 24 hr) were subjected to ChIP-seq for defining ERa-bound DEREs. Fusion frequencies of
breakpoint sites are plotted in purple and binding intensities of ERa-bound DEREs in blue (untreated) and red (E2-treated). See also Figures S2A and S2B for
whole-genome and individual chromosome maps, respectively.
(C) Pie chart summarizing all fusion events in MCF-7 cells based on mate-pair sequencing data.
(D) Distribution of DEREs nearby translocation sites in clustered and non-clustered breakpoints. The number of DEREs per 10 kb span is calculated in each
direction relative to each breakpoint site. The red and blue lines are the average value of DEREs.
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Figure 3. Prolonged Estrogen Exposure
Leads to Amplification of DERE Copies
(A) Interphase FISH analysis of amplified 20q13
DERE copies in E2-treated (70 nM) MCF-7 cells for
different time periods (0, 5, 7, 10, and 25 days).
Representative four images in each condition are
shown. Inserted squares: clustered DEREs.
Quantification of DERE copies per cell was per-
formed by CellSens software and presented in the
scatter plot (n = 20). A spot with area size over
0.3 mm2 was counted as the clustered DERE
region. p < 0.001 (twoway ANOVA test), compared
to ‘‘0’’ group.
(B) Quantitative PCR analysis of two amplified
DERE copies located in 20q13 (upper) and 17q23
(lower). MCF-7 cells were continuously exposed to
E2 (70 nM) and/or ICI 182,780 (100 nM) for different
periods (5, 7, 10, and 25 days) in charcoal-stripped
conditions (n = 6 replicates in two biological
batches of treatment). Mean ± SD. ***p < 0.001
(Student’s t test), compared to ‘‘Ctrl’’ cells.
(C) Dose-dependent gains of 20q13 and 17q23
DERE copy in MCF-7 cells exposed to different
estrogenic chemicals. MCF-7 cells were cultured
in charcoal-stripped conditions and exposed to
ethanol (Ctrl), E2 (70 nM), or estrogenic chemicals
with 5-fold different dose, including diethylstil-
bestrol (DES, 14-70-140 nM), bisphenol A (BPA,
0.5-4-20 nM), 4-nonylphenol (NP, 0.2-1-5 mM),
daidzein (Dai, 2-10-50 mM), N-butyl-benzyl
phthalate (BBP, 2-10-50 mM), di(2-ethylhexyl)-
phthalate (DEHP, 2-10-50 mM), 4,40-dichloro-
biphnyl (PCB, 0.02-0.1-0.5 nM), and 1,3,5-tris
(4-hydroxyphenyl)- 4-propyl-1H-pyrazole (PPT,
0.02-0.1-0.5 nM), respectively, for 5 days. These
treatment doses were selected and modified
based on our previous findings (Hsu et al., 2009,
2010). Genomic DNA from treated cells was
collected for quantitative PCR analysis of 17q23
and 20q13 DERE copies. Mean ±± SD (n = 6 rep-
licates in two biologic batches of treatment). ***p <
0.001 (Student’s t test), compared to ‘‘Ctrl’’ cells.
(D) Differential copy changes of 20q13 and 17q23
DEREs in normal epithelial cells pre-exposed to
estrogenic chemicals. Experimental scheme of an
in vitro exposure system is shown in the upper
panel. Floating mammospheres containing breast
progenitor cells were preexposed to dimethyl
sulfoxide (DMSO as control, Ctrl), E2 (70 nM), or
estrogenic chemicals, including DES (70 nM), BPA
(4 nM), NP (1 mM), Dai (10 mM), BBP (10 mM), DEHP
(10 mM), PCB (0.1 nM), and PPT (0.1 nM),
respectively, for 3 weeks. Differentiated epithelial
cells were then subjected to quantitative PCR
analysis (lower) of 17q23 and 20q13 DERE copies.
Mean ± SD (n = 6 replicates in two batches
of treatment). ***p < 0.001 (Student’s t test),
compared to ‘‘Ctrl’’ cells.
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and 20q13 (Table S8).
Amplified DERE Copies Are Linked to Adverse
Outcomes of ERa-Positive Luminal Breast Cancer
In addition to chromosomal fusions, interphase fluorescence
in situ hybridization (FISH) analysis indicated that DERE copiesin 20q13 were increased with time in E2-treated MCF-7 cells
(Figure 3A; statistics of 20q13 DERE copies shown in right-upper
scatter plot). Notably, long-term E2 exposure also triggered the
formation of DERE clusters (see inserted squares and right-lower
scatter plot). Quantitative PCR analyses further confirmed that
estrogen stimulation significantly led to DERE amplification on
17q23 and 20q13 regions in MCF-7 cells (p < 0.001; Figure 3B).Cancer Cell 24, 197–212, August 12, 2013 ª2013 Elsevier Inc. 201
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Estrogen-Driven DERE Amplification in Breast CancerThe ERa antagonist- ICI 182,780 (ICI, 100 nM) effectively in-
hibited DERE copy increases elicited by E2 (see E2+ICI group).
Based on these results, we hypothesized that prolonged
exposure to estrogenic chemicals contributes to DERE amplifi-
cation. MCF-7 cells were used to determine whether other estro-
genic chemicals recapitulate estrogen-mediated gains of DERE
copy (Hsu et al., 2009, 2010). Seven of the eight compounds
examined, except bisphenol A (BPA), demonstrated increases
in DERE copies on 17q23 and 20q13 in a dose-dependent
manner (p < 0.001; Figure 3C).
To determine whether this estrogen-driven DERE amplifica-
tion occurs in breast stem/progenitor cells, normal mammo-
spheres harboring self-regenerating cells were exposed to E2
or other aforementioned estrogens (Figure 3D, upper). We then
measured changes of DERE copy located on 17q23 and 20q13
in differentiated progeny without additional estrogenic exposure.
In two biologic replicates, increased DERE copies were consis-
tently observed in epithelial cells pre-exposed to E2 or six of the
eight compounds tested (p < 0.01; Figure 3D, lower). One
possible explanation as to differences in drug response between
normal and cancer cells could be due to ‘‘U-shaped’’ dose-
response curves in reaction to particular drugs (Almstrup et al.,
2002; Li et al., 2007; Vandenberg et al., 2006).
Examining DERE copy number in the Integrative Cancer
Biology Program (ICBP) panel of 46 breast cancer and five
immortalized cell lines revealed that DERE copies were signifi-
cantly increased in ERa-positive breast cancer cell lines
compared to ERa-negative cancer and immortalized lines (p <
0.0004 in 20q13 and p < 0.0186 in 17q23; Figure 4A, left).
Furthermore, ERa-positive luminal-A cell lines (Figures S3A
and S3B, dashed red lines) appeared to have on average higher
DERE copies than those of luminal-B subtypes (dashed blue
lines). Quantitative PCR analysis of 105 clinical samples showed
a similar DERE amplification event in ERa-positive breast tumors
(p < 0.0118; Figure 4A, right). The clinical relevance of these
observations illustrated by a Kaplan-Meier analysis demon-
strated that gains of 17q23 and/or 20q13 DERE copy were posi-
tively associated with reduced overall survival in patients with
ERa-positive breast cancer (p < 0.0002; Figure 4B). In contrast,
no association between DERE amplification and survival was
apparent in ERa-negative tumors (p < 0.6452; Figure S3C).
It was next of interest to investigate the association of genomic
rearrangement with DERE amplification in patient samples. We
examined 17q23::20q13, the most frequent structural fusion in
the MCF-7 genome, in 126 primary tissues using PCR analysis
(Figure 4C, upper; Table S4). This fusion fragment was detected
in 15.1% (16 of 106) of tumors, but not in adjacent normal tissues
(Figure 4C, see ‘‘All tumors’’ in bar chart). The majority of fusions
were found in ERa-positive tumors (13 of 16), suggesting that
ERa signaling activation may contribute to both DERE amplifica-
tion and the occurrence of 17q23::20q13 structural fusions. To
determine whether aberrant epigenetic changes of DERE re-
gions influence these structural fusions in MCF-7 cells, we
generated heat maps of DERE receptor binding occupancy
and DNA methylation in DERE receptor binding regions using
the aforementioned ChIP-seq data and our previously published
MeDIP-seq data (Figure 4D; Hsu et al., 2010). We observed that
DEREs occupied by ERa were frequently hypomethylated
compared with their flanking regions, which were hypermethy-202 Cancer Cell 24, 197–212, August 12, 2013 ª2013 Elsevier Inc.lated. Hypomethylated regions are known to be structurally
unstable and prone to develop breakage and fusion in cancer
cells (You and Jones, 2012).
Further in silico analysis identified 133 differentially expressed
genes in three ERa-positive cell lines (600MPE, MDA-MB-361,
and ZR-7530) having fewer 20q13 DERE copies (n < 15) relative
to three other cell lines (LY2, BT474, andMCF-7) with the highest
copy-number gains (n > 50; (Figure S3D and Table S9; Heiser
et al., 2012). Ingenuity pathways analysis (IPA) suggested that
TP53/BRCA1-related DNA damage response in LY2, BT474,
and MCF-7 cells enhanced this aberrant DERE copy increases
(Figures S3E and S3F; Mohr et al., 2011). Upregulated (e.g.,
NBN, DNMT3B, HLTF, and NCOA3) and downregulated (e.g.,
CYP286, SNCG, and RRAS) loci involved in this damage
response pathway likely promote DNA break-repair functions,
leading to amplification of 20q13 DEREs in breast cancer cell
lines. This finding, therefore, provides a future opportunity to
investigate the relationship between DNA-damage regulatory
pathways and DERE amplification in breast cancer.
Taken together, these integrative results strongly indicated
that (1) amplified DERE copies are associated with the develop-
ment of ERa-positive luminal breast cancer and poorer survival
in patients; and (2) this process is a general phenomenon in
both normal and cancer cells exposed to different estrogenic
chemicals. We further suggest that ERa binding sites in 17q23
and 20q13 regions are highly susceptible to breakage and
fusion, contributing to genomic instability in cancer.
Amplified DERE Copies Regulate Target Genes through
Long-Range Chromatin Interactions
To address the biological consequence of DERE amplification,
we investigated the effect of increased DERE copies on tran-
scription of potentially oncogenic target genes using three-
dimensional interphase fluorescence in situ hybridization
(3D-FISH) analysis. A 3D-FISH approach preserving nuclear
architecture of MCF-7 cells showed that DEREs tended to
aggregate in 10–12 subnuclear locations (Figure 5A, right). In
contrast, DEREs were scattered into 50–60 spots in a ‘‘com-
pressed’’ nucleus by traditional 2D-FISH (middle). Consistent
with the ‘‘transcription factory’’ concept (Lieberman-Aiden
et al., 2009; Mitchell and Fraser 2008; Osborne et al., 2007),
DEREs located on different chromosomes might be brought
together to ‘‘subnuclear depots’’ for coordinate transcriptional
control of multiple genes. Upon binding by ERa, DEREs (Fig-
ure 5B, red lines) might reach out through chromatin movement
to interact with target genes while existing contacts (blue lines)
dissociate from target loci in E2-stimulated MCF-7 cells. Inte-
grating our 3C data set with a published time-course study of
gene expression in MCF-7cells (Cicatiello et al., 2010), we map-
ped two groups of target genes, including 95 loci remotely
interacting with 20q13 DEREs and 38 genes with 17q23 DEREs
(Figure 5C). A time-course analysis independently confirmed
that 46 of these estrogen-responsive targets displayed downre-
gulated, upregulated, or cycling patterns of gene expression
over a 24 hr period of E2 stimulation (Figures 5D, S4A, and
S4B). These differential expression profiles regulated by DEREs,
however, were less obvious in normal breast epithelial cells stim-
ulated with E2 (see THRAP1 and ZIM2 as two examples in Fig-
ure 6B, blue line). Integration of our qPCR results of DERE
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Figure 4. Amplification of DERE Copies Preferentially Occurs in ERa-Positive Breast Cancers
(A) Quantitative analysis of 17q23 and 20q13 DERE copies in 51 immortalized and breast cancer cell lines (left) and 105 clinical samples, including 94 breast
tumors and 11 normal tissues (right). Mann-Whitney Rank Sum test was conducted to determine statistical significance. See also Figures S3A and S3B for copy
number of 20q13 and 17q23 DEREs in luminal breast cancer cell lines; Figure S3D–S3F and Table S9 for association of TP53-involved signaling network in 20q13
DERE amplification.
(B) Kaplan-Meier survival curves of ERa-positive breast cancer patients (n = 74) harboring either high (n > 2) or low copy (n < 2) of the 20q13 (left) or 17q23 (middle)
or both (right) DEREs. Wilcoxon test was used to determine statistical significance. See also Figure S3C for overall survival curves of ERa-negative breast cancer
patients (n = 19).
(C) PCR analysis of 17q23::20q13 fusion fragment in 106 primary breast tumors and 20 normal tissues. Genomic location of interrogated fusion is shown in upper
panel. Gel pictures of PCR results from ten representative ER-positive and -negative tumors, respectively, are shown, plus an MCF-7 positive control and H2O
negative control.
(D) Intensity maps of DERE receptor binding upon different periods of E2 treatment and DNA methylation. The flanking regions of DERE (centered) from 2.5 kb
to +2.5 kb were shown. The heat map of DNA methylation in untreated MCF-7 cells was generated using MeDIP-seq data from our previous study (Hsu et al.,
2010).
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breast cancer cell line panel; Heiser et al., 2012) further demon-
strated that increased DERE copies preferentially correlated with
increased or decreased expression levels of E2-responsivegenes in 16 ERa-positive but not 30 ERa-negative cell lines (Fig-
ures 5E and S4C). Among these ICBP cell lines, the LY2 cell line
was an outlier with the greatest number of 17q23 and 20q13
DERE copies, which seemed to have little effect on target geneCancer Cell 24, 197–212, August 12, 2013 ª2013 Elsevier Inc. 203
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Figure 5. Amplified DERE Copies Regulate Target Genes through Estrogen-Induced Chromatin Interactions
(A) Interphase fluorescence in situ hybridization (FISH) analysis of amplified DERE copies in compressed (left and middle) and intact (right) nuclei.
(B) Circos plots depict chromatin interactionsof twoamplifiedDERE (20q13 and17q23)with their respective target genes in untreated (Ctrl) andE2-treatedMCF-7.
(C) Time-course analysis of gene expression synchronously regulated by either 20q13 (upper) or 17q23 (lower) DEREs. Heat maps generated using a published
data set (Cicatiello et al., 2010) show expression patterns of 20q13- or 17q23-interacting genes in response to E2 stimulation.
(D) Independent time-course analysis of 46 estrogen-responsive targets regulated by 20q13 DEREs. Total RNA isolated from E2-treated (70 nM) MCF-7 cells at
different time-points was subjected to quantitative RT-PCR analysis. Based on the data obtained from two independent sets of experiments, four different
patterns of gene expression were identified in E2-treatedMCF-7 cells. Data were summarized in a heat map and shown in 46 bar charts with individual genes (see
Figures S4A and S4B).
(E) Correlation analysis of DERE copy changes and DERE-regulated target gene expression in ERa-positive breast cancer cell lines (n = 16). Expression mi-
croarray data of the ICBP cell lines (Heiser et al., 2012) were integrated with experimental copy-number results to interrogate the correlation between DERE
amplification and transcriptional regulation. Down- and upregulated genes were identified from Figure 5C. Linear regression analysis was used to determine
statistical significance. See also Figure S4C for correlation analysis in ERa-negative breast cancer cell lines (n = 30).
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remotely modulate transcriptional control of distant genes
through long-range chromatin interactions in estrogen/ERa-d-
riven tumorigenesis.
Amplified DERE Copies Repress Candidate Tumor-
Suppressor Loci and Drive Cell Proliferation of
ERa-Positive Luminal Cancers
To confirm long-range transcription regulation by DEREs, we
conducted functional analyses of two selected target loci,
THRAP1 (or MED13) and ZIM2. The rationale for choosing
THRAP1 was that its gene product is an integral component of
the repressive Mediator complex recently implicated in tumor
growth (Monni et al., 2001; Knuesel et al., 2009). ZIM2 was
also selected because its biologic functions have not been
explored in breast cancer. As a zinc-finger imprinted gene local-
ized on 19q13, ZIM2 plays a regulatory role for axon guidance
signaling involved in pancreatic cancer development (Biankin
et al., 2012; Kim et al., 2004). We conducted chromosome
conformation capture (3C)-qPCR assay to examine whether
DEREs located on 17q23 and 20q13 can remotely regulate
THRAP1 and ZIM2. In MCF-7 cells stimulated with E2 over a
24 hr period, interchromosomal interactions were more
frequently observed between DEREs located on 20q13 and
the THRAP1 gene (+0.2 and 2.9 kb flanking regions of TSS)
and the ZIM2 promoter regions (1.7, 4.2, and 4.4 kb; Fig-
ure 6A, left and right). Intra-chromosomal interactions were
also observed between 17q23 DEREs and THRAP1 gene-body
regions (i.e., exon 13–14 regions located +52 and +48 kb from
TSS), indicating cooperative efforts between different DEREs
in regulating gene expression (Figure 6A, left and middle). Inter-
and intrachromosomal interactions associated with progressive
downregulation of the two loci in E2-stimulatedMCF-7 cells (Fig-
ure 6B, red line). However, siRNA knockdown of ERa (Figure S5)
markedly attenuated these inter- and intrachromosomal interac-
tions, abrogating the time-course repression of these genes
(Figures 6A and 6B, dashed-dotted red lines). Compared to
MCF-7 cells with 50–60 copies of amplified 20q13 segment (Fig-
ures 3A, 3B, and 5A), the effect of this chromatin-mediated
repression was substantially less in normal breast epithelial cells
with only two copies (Figure 5A, normal epithelial cells). Upon E2
stimulation, chromatin interactions in normal cells were less
frequent with only a slight effect on gene repression (Figure 6B,
blue line).
Because epigenetic changes are known to contribute to tran-
scription repression and these long-range chromosomal interac-
tions may lead to histone modifications in target regions (You
and Jones, 2012), we determined genomic landscapes of three
histone marks- H3K4me3, H3K9me3, and H3K27me3 and RNA
polymerase II (Pol II) in the two loci using a published data set
for MCF-7 cells (Joseph et al., 2010). Using THRAP1 as an
example (Figure 6C, left), E2 stimulation resulted in an increase
in the H3K27me3 (red bar) repressive mark occupancy on pro-
moter region and simultaneously decreased Pol II binding (green
bar) at its transcription start site (TSS). A similar response was
also observed at the ZIM2 locus (Figure 6C, right). Upon E2 treat-
ment, increased recruitment of repressive H3K9me3 (red bar) to
the TSS region was accompanied reduced H3K4me3, an active
histone mark, and less Pol II binding (green bars).To further investigate the biologic significance of THRAP1 and
ZIM2 in breast tumorigenesis, proliferation of MCF-7 cells tran-
siently transfected with either THRAP1 or ZIM2 was monitored
using the foci formationassay.THRAP1orZIM2expression levels
in the transfected cells were confirmed using RT-qPCR analysis
(Figure S6). Repressed THRAP1 and ZIM2 by DEREs likely
contributed to the observed E2-stimulated MCF-7 cell
proliferation (Figure 7A, MCF-7). This proliferation was greatly
reduced by transient expression of THRAP1 or ZIM2, suggesting
that these twogenesplay tumor-suppressor roles in ERa-positive
luminal cancer cells (p < 0.001; Figure 7A). In silico analysis of an
expression microarray data set (Curtis et al., 2012) further
confirmed downregulation of THRAP1 or ZIM2 in ERa-positive
luminal-A tumors relative to other breast cancer subtypes (p <
0.05, Figure 7B). An inverse correlation between increased
DERE copies on 20q13 and downregulation of these two genes
was further observed (p < 0.01; Figure 7C). Consistent with these
findings, estrogen-induced DERE copy gains possibly initiated in
progenitors chronically preexposed to estrogenic chemicals
resulted in permanent expression changes of THRAP1 or ZIM2
in the progeny (Figure 7D). Taken together, these results indicate
that DERE-mediated transcriptional regulation may result in
repression of tumor suppressor genes such as THRAP1 and
ZIM2, leading toaberrant cell proliferationand tumorprogression.
AmplifiedDERECopiesDeregulate Antiproliferation and
Apoptosis Signaling Networks Associated with
Tamoxifen Resistance in Breast Cancer
We further examined whether altered expression of DERE-regu-
lated genes associates with adverse treatment outcome of
ERa-positive breast cancer by surveying published expression
microarray data of multiple breast cancer cohorts (Hatzis et al.,
2011; Symmans et al., 2010). We found that differential expres-
sion of a subset (n = 67) of DERE-regulated loci is associated
with patient relapse after endocrine therapies (Figures 8A, 8B,
S7A, and S7B). Comparing gene expression profiles in a 298-
patient cohort (Symmans et al., 2010), 40 of the 67 DERE-inter-
acting loci were significantly repressed in primary tumors from
71 patients, who subsequently developed local recurrence or
distant metastasis after 5 years of tamoxifen therapy (p <
0.0001, Figure 8A). In contrast, only 27 of the 67 DERE-interact-
ing loci were upregulated in those same patients (p < 0.0001,
Figure 8B). To validate the above findings, 26 of the 67 DERE-
regulated loci were randomly selected for gene expression anal-
ysis in an ERa-positive BT474 breast cancer cell line, which is
HER2-overexpressing and resistant to tamoxifen (Wang et al.,
2006). Increased crosstalk between ERa and HER2 pathways
may contribute to endocrine resistance in this cell line. Estrogen
stimulation significantly induced differential expression of those
genes in both MCF-7 and BT474 cells while ICI attenuated E2-
driven up- and/or downregulation only in MCF-7, but not
BT474 cells (Figures 8C, 8D, S7C, and S7D). One possible expla-
nation for this observation is that HER2 may bypass the ERa
blockade to regulate DERE-interacting loci in BT474 cells. An
alternative explanation is that despite the ICI treatment, high
copy-number DEREs in BT474 cells may provide an additional
ERa binding reservoir for partial transcription regulation of these
target genes (Figures S3A, S3B, S7C, and S7D). An IPA
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including cell cycle control (e.g., G2/M DNA damage checkpoint
regulation and CDC42 signaling) pathways (Figure 8E). Downre-
gulated genes belonged to signaling pathways such as antipro-
liferative somatosatin receptor 2 and SAPK/JNK signaling, which
has been associated with tamoxifen-induced apoptosis (Man-
dlekar and Kong, 2001). Signaling cascadesmodified by upregu-
lated genes included attenuation of Granzyme B-associated
apoptosis, leading to advanced luminal cancer development
(Jiang et al., 2006).
DISCUSSION
Genomic amplification in 17q23 and 20q13 regions is commonly
observed in breast cancer with poor prognosis (Andersen et al.,
2002; Bilal et al., 2012; Ginestier et al., 2006). Moreover, these
amplification events have been implicated in endocrine therapy
(Bilal et al., 2012; Han et al., 2006; Symmans et al., 2010). Spe-
cifically, Han et al. (2006) reported that chromosome 17q23 is
among the most commonly amplified regions in patients with
breast cancer whose tumors recurred within 5 years of post-
tamoxifen therapy. It was previously suggested that oncogenes
located within these amplicons express high levels of corre-
sponding mRNA and proteins involved in cancer development
and tamoxifen resistance. As a result, identifying driver genes
located within these large amplified regions (4.5 Mb for 17q23
and 19 Mb for 20q13) was subject to intense investigations
(Collins et al., 2001; Han et al., 2006; Monni et al., 2001; Sinclair
et al., 2003). However, systematic screening of a total of 148
genes in these regions identified only a handful of putative onco-
genes. For example, overexpression of ZNF217 and MAP3K3
located on 20q13 can attenuate apopototic signaling, leading
to chemotherapy resistance (Ginestier et al., 2006; Santarius
et al., 2010). In the 17q23 region, overexpression of RPS6KB1,
TBX2, PPM1D, RAD51C, and APPBP2 frequently associates
with tumors displaying luminal or HER2 phenotypes (Bilal et al.,
2012; Monni et al., 2001; Sinclair et al., 2003). One proposed
explanation for the low number of oncogenes associated with
these amplified regions is that selection of only a few oncogenic
drivers is sufficient to drive tumorigenesis in these cell types. This
process may be accompanied by amplification of neighboring
genes as neutral passengers (Ginestier et al., 2006; Sinclair
et al., 2003).Figure 6. Two Representative Examples of Amplified DERE-regulated
(A) Chromosome conformation capture coupledwith quantitative PCR (3C-qPCR)
treated MCF-7 and normal epithelial cells was digested with either BamHI or Hind
as ‘‘baits,’’ and digested areas of two candidate loci, ZIM2 and THRAP1, were ‘‘in
shown as relative interaction frequencies compared to those of GAPDH as an in
(B) Expression analyses of THRAP1 and ZIM2 in normal breast epithelial cells (
quantitative RT-PCR. Cells with or without ESR1 (ERa) knockdown by siRNA we
siRNA on ESR1 expression.
(C) Genomic landscapes of histonemodifications and Pol II occupancy on THRAP
three histone marks (H3K4me3, H3K9me3, and H3K27me3) and Pol II was used to
upstream region of transcription start sites to transcription termination sites (Jos
pancy.
(D) Proposed coordinate model of DERE-modulated chromatin interactions for tra
are brought to THRAP1 (at 17q23.2) and ZIM2 (at 19q13.43), respectively, throug
continuous estrogen exposure, genomic fusions and amplifications occur in the
unstable cancer genome. The DEREs from 20q13 are replicated and inserted into
DEREs and the respective gene loci, which profoundly alter their transcriptionalIn the present study, we offer an additional explanation that
DNA regulatory elements located within these genomic regions,
such as DEREs, are co-amplified during breast tumorigenesis.
We suggest that increases in DERE copy number enhance
ERa-modulated transcriptional activity activated by E2, which
is associated with induction of pro-growth factors as well as
repression of growth suppressing genes (Carroll et al., 2006;
Fullwood et al., 2009; Welboren et al., 2009). An integrative anal-
ysis of next-generation sequencing data indicated that densely
ERa-bound DEREs (46–51 per megabase) are localized in
17q23 and 20q13 regions. These ERa-bound DEREs interact
with target genes outside the amplified regions through long-
range chromosomal interactions. Our experimental evidence
further reveals that the amplified DERE copies enhance the fre-
quency of chromatin interactions in breast cancer cells, mark-
edly altering transcriptomic profiles of target genes involved in
cancer development. In silico analysis shows that these genes
exist in a network associated with apoptotic signaling pathways,
such as the serine proteases, Granzyme B (Han et al., 2005). The
observed increase in the frequency of chromatin interactions be-
tween amplified DEREs and target genes likely attenuate Gran-
zyme B-induced apoptosis, thereby contributing to advanced
luminal cancer development (Jiang et al., 2006). Moreover,
based on differential expression patterns in tamoxifen-sensitive
MCF-7 versus tamoxifen-resistant BT474 cells (Figures 8C, 8D,
S7C, and S7D), we propose that amplified DEREs may deregu-
late gene expression associated with anti-proliferation and
apoptosis signaling networks that are implicated in tamoxifen
resistance. Although the estrogen-dependent transcription
mechanism may be blocked by tamoxifen, tumors containing
high copy-number DEREs may still have residual responses to
estrogen-dependent growth compared to tumors with low
copy-number DEREs. As such, it will be interesting to interrogate
whether high copy-number DEREs can be used as putative bio-
markers for predicting patients’ intrinsic resistance to endocrine
therapy.
In addition to the aforementioned findings, this study further
demonstrates that amplified DNA regulatory elements are
caused by sustained stimulation of DERE-DERE interactions
(Figures 1, 2, and S2). In tumorigenesis, these amplified events
may intensify chromatin interactions (see two examples in
Figure 6D), leading to inter- and intrachromosomal rearrange-
ments. Although the molecular mechanisms underlying theseTarget Genes through Long-Range Chromatin Interactions
analysis of two target loci, ZIM2 and THRAP1. Cross-linked chromatin fromE2-
III and then ligated under diluted conditions. DEREs at 20q13 were designated
terrogated fragments.’’ Ligated DNA was subjected to the 3C-qPCR. Data are
ternal control. Mean ± SD (n = 6).
HMEC) or cancer cells (MCF-7) in response to E2 (70 nM) determining using
re treated with E2 for the indicated times. See also Figure S5 for the effect of
1 andZIM2 loci upon estrogen stimulation. A published ChIP-seq data including
investigate the occupancy of epigenetic marks on the two genes from20 kb
eph et al., 2010). Red bars, increased occupancy; green bars, reduced occu-
nscriptional regulation in response to estrogen. In normal cells, DEREs at 20q13
h chromatin movement to repress expression. During tumor progression under
20q13 DEREs attributed to prolonged physical contact between DEREs in an
different chromosomes, leading to increased interaction frequencies between
regulation.




Figure 7. Amplified DEREs Repress Candi-
date Tumor Suppressor Expression for
ERa-Positive Luminal Cancer Proliferation
(A) Determining tumor-suppressor features of two
DERE-regulated loci, THRAP1 and ZIM2, in
MCF-7 cells. To determine cell proliferation rate,
colony formation assays were conducted in cells
transiently expressing THRAP1 or ZIM2, respec-
tively, upon E2 stimulation (70 nM; see also Fig-
ure S6 for expression levels of THRAP1 and ZIM2
in MCF-7 transfectants). Colony numbers of two
biologic replicates scored by three independent
researchers are shown (right). ***p < 0.001 (Stu-
dent’s t test), compared to ‘‘MCF-7’’ group.
(B and C) In silico analysis of THRAP1 and ZIM2
mRNA expression levels in breast cancer sub-
groups (B) and ERa-positive breast tumors within
differential copies of 20q13 and 17q23 DEREs (C)
using a published microarray breast cancer cohort
(Curtis et al., 2012). A total of 1986 breast tumors
with subgroup information were analyzed in (B); 68
ERa-positive breast tumors within amplification of
either 17q23 or 20q13 DEREs were applied in the
study.
(D) Expression levels of THRAP1 and ZIM2 in
normal breast epithelia preexposed to estrogenic
chemicals as shown in Figure 3D. THRAP1 and
ZIM2 expression was determined by RT-qPCR of
differentiated epithelial progeny after preexposure
to estrogenic chemicals (see exposure scheme in
Figure3D,upper).Mean±SD (n=6 replicates in two
batches of treatment). ***p < 0.001; **p < 0.01; *p <
0.05 (Student’s t test), comparing to ‘‘Ctrl’’ cells.
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Estrogen-Driven DERE Amplification in Breast Cancerchromosomal amplifications in cancer remain to be fully
explored, we anticipate that E2-stimulated, DERE-mediated
chromatin interactions may be a driving force of genomic insta-
bility. It is well established that loss of genome stability and integ-
rity is a hallmark of cancers, leading to somatic copy-number
alterations and nonrandom distributions of breakpoints (De
and Michor 2011a; Hampton et al., 2009). Our results suggest
that DNA breakpoints preferentially cluster together at specific
chromosomal regions previously implicated in breast tumorigen-208 Cancer Cell 24, 197–212, August 12, 2013 ª2013 Elsevier Inc.esis, indicating that those regions
harboring clustered breakpoints are
exquisitely prone to genomic rearrange-
ments (De and Michor 2011b; Hampton
et al., 2009). Furthermore, during
neoplastic transformation, defects in
double-strand break repair can occur
(Hampton et al., 2009), destabilizing
these physical interactions and promot-
ing insertions and self-duplication of
20q13 DERE clusters, for example, into
regions of seven derivative chromosomes
(Figures S2C and S2D).
While our ChIP-seq and 3C-seq
analyses point to amplification DERE-
mediated interactions, normalization to
copy-number variation of DEREs is not
presently conducted for several reasons.First, the occurrence of ERa-binding events or the frequency of
chromatin interactions may not linearly correspond to increased
DERE copies. Second, while applying normalization to DERE
copies relies on an assumption that all amplified copies in a given
DERE locus participate evenly in ERa-binding and associated
chromatin interaction, not all copies are expected to contribute
equally to these events. Lastly, DERE-mediated chromatin inter-
actions are highly dynamic upon estrogen stimulation, irrespec-





Figure 8. Expression Signature of DERE-Interacting Genes Correlates with Relapse after Tamoxifen Therapy
(A and B) In silico analysis of DERE-regulated genes in an ERa-positive breast tumor cohort is associated with relapse. A breast cancer cohort including a total of
298 patients with ERa-positive breast tumors and 5-year tamoxifen treatment was used to study the clinical significance of DERE-regulated genes (Symmans
et al., 2010). Forty downregulated (A) and 27 upregulated (B) genes were significantly associated with relapse after tamoxifen treatment (p < 0.0001, Mann-
Whitney Rank Sum test; see also Figures S7A and S7B for validation analysis using another independent cohort within endocrine therapy history).
(legend continued on next page)
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tion may lead to progressive increases and then decreases in
DERE interactions between 17q23 and 20q13 over a 24 hr period
(data not shown; Lieberman-Aiden et al., 2009). Therefore, the
present analysis supports the concept that estrogenic exposure
drives genomic alterations involving chromosomal amplification
of distant estrogen-responsive regulatory elements. These
genetic lesions persist in breast progenitor cells, and when
accompanied by altered gene expression profiles, possibly
lead to tumorigenesis. In addition, our data suggest that ampli-
fied regulatory elements in 17q23 and 20q13 can be used as
potential prognostic markers for anti-estrogen resistance.
EXPERIMENTAL PROCEDURES
Amore detailed description of the experimental procedures and reagents used
in this study can be found in the Supplemental Experimental Procedures.
Breast Tissue Collection and In Vitro Exposure Model
Noncancerous and cancer samples were collected by the tissue procurement
service in accordance with the protocols approved by the Institutional Review
Board of TheOhio State University and had been de-identified prior to the anal-
ysis. For isolation of breast progenitor cells, noncancerous sections were
obtained from individuals undergoing reduction mammoplasties mainly due
to macromastia. These tissues were dissociated mechanically and enzymati-
cally, and single cells were isolated and grown into progenitor-containing cells,
called mammospheres (2,000–10,000 cells per mammosphere), in ultra-low
attachment plates (Corning) with serum-free mammary epithelial growth
medium (Cambrex) as described (Dontu et al., 2003). Progenitor cells, repopu-
lated in the suspension culture up to six passageswere then exposed toDMSO
(dimethyl sulfoxide, control), 17b-estradiol (E2), or estrogenic chemicals in
phenol red–free medium for 3 weeks (medium changed twice weekly). After
pre-exposure, progenitor-containing cells were placed on a collagen substra-
tum (BD Biosciences) in phenol red-free medium for 2–3 weeks without addi-
tional exposure. Under these culture conditions, progenitors were differenti-
ated into mature breast epithelial cells as described previously (Hsu et al.,
2009, 2010). Six sets of biologic replicates were interrogated in this study.
The MCF-7 and BT474 breast cancer cell line, obtained from the American
Type Culture Collection, were maintained in phenol red-free medium. To mini-
mize the effect of endogenous estrogen on each experiment, MCF-7 and
BT474 cells were cultured in media containing charcoal-stripped serum for
24 hr prior to any short-term (a 24 hr period) treatment. For long-term exposure,
cells were cultured in charcoal-stripped serum condition with any treatment.
Library Preparation and Illumina Sequencing Processing of ChIP-
seq, 3C-seq, and Mate-pair Seq
ChIP-seq, 3C-seq, and mate-pair seq libraries were prepared using the Illu-
mina ChIP-seq, paired-end, and mate-pair sample preparation kits, respec-
tively, according to the manufacturer. Libraries were validated using Agilent
Technologies 2100 Bioanalyzer and then sequenced on Genome Analyzer
IIx sequencer as follows: 3C-seq, 2 3 36 bp; mate-pair seq, 2 3 51 bp;
ChIP-seq, 1 3 51 bp. Detailed experimental description and data analyses
are provided in the Supplemental Experimental Procedures.
Statistical Analyses
All quantitative PCR results were presented as themean ± SDof n independent
measurements. Statistical comparisons between the two groups were made
by Student’s t test using SigmaPlot 11, and multiple groups were determined(C and D) Expression analysis of 26 DERE-interacting genes Involved in tamoxifen
cells treatedwith E2 (70 nM) alone/and ERa antagonist ICI 182,780 (ICI, 1 mM) in five
with individual genes (see also Figures S7C and S7D). Mean ± SD (n = 6 replicate
(E) Signaling pathways associated with DERE-regulated genes in tamoxifen resis
and upregulated genes (identified from A and B) in tamoxifen resistance. Mean ±
0.05 (Student’s t test), compared to control cells (time point ‘‘0 hr’’).
210 Cancer Cell 24, 197–212, August 12, 2013 ª2013 Elsevier Inc.by ANOVA test. For samples with equal variance, the paired Student’s t test
was used. For samples with unequal variance, the Mann-Whitney Rank Sum
test was utilized.ACCESSION NUMBERS
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